Goldline Pharmaceutical IPO Details: Price, Dates & Financials

Shares reserved for the market maker in Goldline Pharmaceutical IPO: Up to ₹1 Cr. The market maker provides two-way quotes after listing to keep the stock liquid.

Pre-issue shareholding: 6,900,000 shares. Post-issue shareholding: 9,600,000 shares.

Goldline Pharmaceutical IPO is a Fresh capital only issue. Issue type: Bookbuilding IPO. Face value is ₹10.

The Red Herring Prospectus (RHP) of Goldline Pharmaceutical IPO is available on the website of the lead manager and the stock exchange (BSE SME) — see the lead manager links on the main page.

The DRHP is the initial offer document filed for regulatory review, while the RHP includes updated disclosures, final issue details, and the price band (when announced). Comparing both documents helps investors identify changes in the Goldline Pharmaceutical IPO's financial information, risks, and offer terms before investing in the Goldline Pharmaceutical IPO. Reviewing both documents provides a clearer understanding of the Goldline Pharmaceutical IPO before making an investment decision.

The DRHP and RHP of the Goldline Pharmaceutical IPO disclose potential risks related to the company's business, financial performance, legal matters, and industry conditions. Reviewing these documents helps investors identify potential concerns about the Goldline Pharmaceutical IPO, evaluate the Goldline Pharmaceutical IPO's risk factors, and make a more informed decision before investing in the Goldline Pharmaceutical IPO.